Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.45 |
| ▸ | MGLL | Q99685 | 5/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30328725 | 0.90 | MGLL (0.44) | P2RX3P2RX2LIPEABHD6MGLL | |
| SCHEMBL30328741 | 0.90 | MGLL (0.56) | LIPEMGLLGPR119 | |
| SCHEMBL30327950 | 0.85 | GPR119 (0.50) | LIPEMGLLGPR119 | |
| SCHEMBL30409877 | 0.85 | DDB1 (0.43) | P2RX3P2RX2GPR119 | |
| SCHEMBL30721149 | 0.85 | DDB1 (0.43) | P2RX3P2RX2GPR119 | |
| SCHEMBL18291231 | 0.85 | P2RX3 (0.42) | P2RX3P2RX2ABHD6MGLLGPR119 | |
| SCHEMBL21606917 | 0.84 | GPR119 (0.60) | P2RX3P2RX2LIPEGPR119 | |
| SCHEMBL30785413 | 0.84 | GPR119 (0.60) | P2RX3P2RX2LIPEGPR119 | |
| SCHEMBL18357554 | 0.83 | ABHD6 (0.53) | P2RX3P2RX2LIPEABHD6MGLL | |
| SCHEMBL25255551 | 0.82 | GPR119 (0.45) | P2RX3P2RX2ABHD6MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | P2RX3 227/4885P2RX2 239/4885LIPE 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.